New GVHD Treatments and Trials: What to Check Before Traveling to China

EastMedGo Nov 6, 2026

If you are looking for a new treatment for graft-versus-host disease (GVHD) after an allogeneic stem cell transplant, first ask your original transplant team whether your current condition allows time for screening and travel. Then check whether the proposed treatment is approved routine care or research; eligibility, costs, and follow-up differ between these two routes. A hospital receiving your records, or a registry page showing “recruiting,” does not mean you have been enrolled.

If you have a fever, chills, or a sudden change in your condition now, seek care first. Do not wait for a cross-border consultation or a research team's reply. Contact your transplant team immediately if your temperature reaches 38°C, you have chills, or you have other signs of infection. If you cannot reach the team or get timely care, go to the nearest emergency department. For difficulty breathing, chest pain, changes in awareness, heavy bleeding, or rapid deterioration, go to the nearest emergency department immediately or call local emergency services; in mainland China, dial 120. Tell the medical staff that you have had an allogeneic transplant, which immunosuppressive medicines you take, and whether you are participating in research. If your team has given you temperature or symptom thresholds for seeking help sooner, follow those instructions.[1]

Key Points

Prevention before transplant, treatment of acute GVHD, and treatment of chronic GVHD are different issues. Even when the medicine has the same name, check the indication, patient population, and prior treatment requirements.
Approval does not guarantee that the hospital has the medicine, that it is suitable for you, or that insurance will cover it. Trial registration and passing preliminary screening do not mean final enrollment. Ask the specific study center to confirm its current status and next steps in writing.
In mainland China, sponsors and institutions conducting drug clinical trials must not charge participants fees related to the trial. Sponsors must also provide trial medicines free of charge and pay for related medical tests. Responsibility for routine treatment, travel, and other costs must be checked item by item; specific responsibilities also apply to trial-related harm.[2]
Do not stop medicines, reduce steroids, or delay emergency care on your own to qualify for research. If monitoring in both countries and continued care after withdrawal cannot be assured, ask the teams to address this gap first.

First, Clarify What the Treatment Is Intended For

GVHD can affect the skin, gut, liver, eyes, mouth, lungs, and other parts of the body. Distinguishing acute from chronic GVHD requires assessment of clinical features; do not classify it yourself based only on the number of days since transplant. Symptoms may also result from infection, medicines, or other causes and need assessment by your transplant team.[3]

Place the news report or proposed treatment into one of these three categories:

Your situation	What to check
You have not yet had a transplant and want to reduce GVHD risk	Donor matching, conditioning, and the prevention regimen. Prevention results cannot be treated as evidence of effectiveness after GVHD has developed.
You have acute GVHD and still have symptoms after treatment	Affected organs, severity, infections, and response to steroids or other treatments.
You have chronic GVHD with persistent or recurring symptoms	Which organs still have active problems, previous treatments, and side effects. Reducing inflammation may not immediately restore function that has already been damaged.

If a doctor uses the term “steroid-refractory,” ask what specifically supports that assessment. Worsening symptoms, recurrence after reducing medicines, and inability to continue because of side effects are separate situations that need to be explained individually. A 2026 evidence-based review by the American Society for Transplantation and Cellular Therapy identifies glucocorticoids as the foundation of systemic treatment for acute GVHD and ruxolitinib as the standard second-line option for steroid-refractory acute GVHD. Individual treatment still needs to account for infections, organ condition, and local availability.[4]

How to Check Approval and Research Status

Ask the hospital or research team for the product's generic name, full formulation name, proposed indication, jurisdiction where it applies, approval document or study number, and the hospital campus where treatment will take place. Then ask your treating team whether it is suitable for you. Approval and actual availability require separate confirmation.

The following are examples identified as of November 6, 2026. They are not a list of all available options:

Product or study	Scope supported by the documents	What this means for patients
Ruxolitinib in mainland China	The manufacturer's published indications for both acute and chronic GVHD cover patients aged 12 years and older who have had an inadequate response to glucocorticoids or other systemic treatments.[5]	Ask the receiving hospital to check the latest Chinese prescribing information, your specific condition, and stock availability. Do not change medicines yourself based on this information.
Belumosudil in mainland China	Chinese prescribing information revised in January 2026: patients aged 12 years and older with chronic GVHD who have had an inadequate response to glucocorticoids or other systemic treatments.[6]	The wording of the Chinese and US indications differs. Confirm against the latest prescribing information where the medicine will actually be used.
Amimestrocel injection in mainland China	The Chinese-language announcement from the national drug regulator says “over 14 years,” while the English announcement says “14 years and older.” Both limit use to acute GVHD with predominantly gastrointestinal involvement after steroid treatment has failed.[7]	If the patient is exactly 14 years old, ask the hospital to confirm eligibility against the current Chinese prescribing information. This is one specific umbilical cord-derived cell product; it does not mean that all stem cell preparations are approved or that it is suitable for all chronic GVHD.
Axatilimab in the United States	FDA-approved for adults and children with chronic GVHD who weigh at least 40 kilograms and have failed at least two prior lines of systemic treatment.[8]	US approval does not establish that it is also approved in mainland China, that a hospital can supply it, or that you qualify.
Ryoncil in the United States	The FDA approved a specific bone marrow-derived cell product for steroid-refractory acute GVHD in children aged 2 months and older.[9]	This approval cannot be applied to cell products from other sources or to unspecified cell products.

If a provider says a treatment is “approved,” request verifiable approval documents and the current prescribing information. If it is described as “research,” request the full study name, registration number, investigator, institution, and ethics review information. Unverified claims about “stem cell therapy” or news of overseas approval cannot replace these documents. Do not pay into personal accounts. If you have concerns, first check with the hospital's clinical research management department or ethics committee.

How to Assess Research Evidence and Opportunities to Apply

First, find the original study or the evidence supporting approval, and ask four questions: Who was studied? What was the treatment compared with? What outcome was measured, and when? How many people had serious adverse events? “Overall response” may include partial responses. A response on day 28 cannot be directly equated with long-term survival. Especially when there is no comparison group or the sample is very small, do not treat the response rate as your own probability of treatment success.

For example, a multicenter, randomized phase 3 study in China examined replacing mycophenolate mofetil with ruxolitinib in a prevention regimen for patients with specific blood cancers undergoing their first myeloablative haploidentical transplant. This was a prevention study. It cannot answer how medicines should be changed once GVHD has developed, and patients should not add a medicine to their existing regimen on their own.[10]

Another example is NCT06585774. Its registered protocol compares axatilimab plus steroids with placebo plus steroids as initial treatment for chronic GVHD. Both groups receive steroids as specified in the protocol. This is a study design, not proof of benefit as first-line treatment. The overall status shown in the registry can change and does not establish that a particular center in China has places available.[11]

Once you have a study number, ask the study center directly: “Is this cohort at this hospital campus currently open? Do you accept patients from overseas? Based on my acute or chronic GVHD type, age, organ involvement, infections, and previous medicines, is formal screening worth pursuing? Where will screening take place, and how long will it take?” Ask for a written reply stating the reply date, contact person, next step, and how long the information remains valid. Even after the center confirms that you may proceed to screening, you must still sign informed consent and complete the required tests. The research team makes the final decision under the protocol. Also agree in advance how your original team will continue your care if screening is unsuccessful or while you wait.

What to Prepare Before Sending Medical Records

Ask your original transplant center to help prepare existing records. Do not stop medicines or arrange extra tests on your own just to complete the list:

A one-page summary: underlying disease and current status, transplant date, donor and cell source, conditioning and GVHD prevention regimens, and the transplant center's contact details.
GVHD onset and diagnosis, affected organs, symptoms, and a timeline of changes. Attach complete reports of any existing pathology, imaging, lung function tests, blood counts, liver and kidney function tests, and infection tests. Include identified organisms and any available antimicrobial susceptibility results for significant infections.
Generic names, doses, start and stop dates, responses, and reasons for stopping all current and previous medicines, including steroids, immunosuppressants, medicines to prevent infection, and other medicines. Ask the doctor to explain which symptoms changed after medicines were reduced.
Write down the problems you most want to address, your expected departure date, and how long you can stay. Before sending the necessary records, confirm with the hospital a secure transfer method, translation requirements, and the receiving department. Ask the recipient to confirm that the files can be opened and passed to the transplant team.

The receiving team may request additional tests or consider travel unsuitable at present. Receipt of records is only the start. Ask when you can expect preliminary advice and who will follow up on pending results.

What to Ask About Costs, Research-Related Harm, and Withdrawal

First, confirm the project's legal status and the rules that apply:

Drug clinical trials: Article 8 of mainland China's Regulations for the Implementation of the Drug Administration Law states that sponsors and drug clinical trial institutions must not charge participants fees related to the clinical trial. Article 45 of the Good Clinical Practice for Drug Trials, revised in 2026, also requires sponsors to provide trial medicines free of charge, pay for medical tests related to the clinical trial, and cover diagnosis and treatment costs for trial-related harm, along with the corresponding compensation or damages.[2] Whether specific harm is related to the trial and who is responsible must be determined according to the facts and applicable rules.
Clinical research within the scope of the Regulations on the Administration of Clinical Research and Clinical Translational Application of New Biomedical Technologies: Article 20 states that institutions initiating clinical research and research institutions must not charge participants fees related to this type of clinical research.[15] This provision cannot automatically be applied to all cell products or clinical translational applications.
Investigator-initiated clinical research conducted by healthcare institutions: The relevant administrative measures strictly prohibit institutions or investigators from improperly charging participants research-related fees.[12] Other rules may also apply to a particular project; ask the institution to explain.

Ask the study center and the hospital's finance department for an itemized written list showing the currency, amount or estimate, and who pays at each stage: screening without enrollment, enrollment, and withdrawal:

Trial medicines, tests required by the protocol, and additional tests; which items count as research-related and who decides.
Routine medicines and care for existing diseases, hospitalization for infections that develop, emergency care, and blood transfusions. If research-related harm occurs, how it is reported and assessed, how immediate treatment is provided, and how to contact the sponsor or ethics committee.
Translation, caregiver support, visas, transport, accommodation, and tests after returning home; whether insurance covers these costs and whether you must pay upfront.

If you are asked to pay research-related fees, first ask the research institution's management department to explain the rules that apply to the project, the nature of the charges, and their written basis. If necessary, raise the issue with the ethics committee and the relevant local authority. Do not treat cost clauses in an informed consent form as grounds for removing legal responsibilities. Mark unquoted items as awaiting confirmation; “the trial is free” does not mean all costs are covered.

Before giving informed consent, allow time to ask about random assignment, possible use of a placebo, foreseeable risks, alternatives, management of harm, contact details for the investigator and ethics committee, and plans after withdrawal. In mainland China, for research covered by the Measures for the Ethical Review of Life Science and Medical Research Involving Humans, participants or their guardians may withdraw unconditionally at any stage without the investigator's approval.[16] The decision to withdraw and arrangements for treatment safety are separate matters. Discuss safe follow-up and continuity of treatment with the investigator and your original transplant team as soon as possible. Do not abruptly stop medicines on your own.

How to Coordinate Departure, Your Stay, and Your Return Home

Before departure, ask your original transplant team and the receiving team in China to jointly confirm whether your current infection and organ status allow waiting and travel, and who will see you and how your original treatment will continue if screening is unsuccessful. Arrange travel after receiving the center's reply. Preliminary remote advice does not mean you have been accepted for admission or are guaranteed fit to fly.

Plan separately for screening, waiting for results, treatment administration, observation, follow-up tests, and a possible longer stay. Ask the research team to specify whether each visit can take place in your country of residence, whether it must take place at the study center, and who will receive abnormal results. If you cannot meet the protocol requirements, do not assume remote follow-up will necessarily be possible after enrollment.

List all medicines and ensure you have enough to cover the trip and delays. Check with the prescribing doctor and relevant authorities in both countries about prescriptions, legal transport, storage, and replacement supplies. Do not assume you can take a study medicine home or buy it locally. Carry your transplant summary, medicine list, contact details, and emergency card with you.

Before returning home, obtain a discharge summary or summary of the completed study stage, the latest test results, a medicine list, and the date of your next follow-up. Have your original team or a local transplant doctor confirm arrangements for taking over care, prescribing, and testing. Ask the team in China to document which results are still pending, who will notify you and the doctor taking over your care, and whom to contact if your condition worsens. Completing a trial, withdrawing from a trial, hospital discharge, and fitness to travel are separate decisions, each requiring confirmation by the relevant team.

Frequently Asked Questions

Does having a registration number mean I can enroll?

No. A registration number helps identify the protocol. The study center must confirm the current hospital campus, cohort, conditions for accepting overseas patients, and your individual eligibility. The registry status may be out of date.

Can I continue my original medicines if I do not pass screening?

Before screening, ask your original team and the investigator to agree on a plan for continued care. Whether to continue medicines and whether the study requires a washout period depend on the protocol and your condition. Do not stop medicines on your own to meet eligibility requirements.

If a Chinese hospital says it offers “cell therapy,” does that mean it has regulatory approval?

No. Request the specific product's full name, the status under which it will be administered, and the approval document or study number. Check the indication and the institution administering it. Products made from different cell sources or using different preparation processes are not interchangeable.[7][9]

If a medicine is available in the United States, will I definitely be able to receive it in China?

Not necessarily. US approval establishes only the indication within US regulatory jurisdiction. The receiving hospital in China must confirm local authorization, supply, costs, and your individual suitability.

Can I try fecal microbiota transplantation myself or treat it like a probiotic?

Do not prepare or use it yourself. Fecal microbiota transplantation differs from ordinary probiotics. The FDA has reported drug-resistant bacterial infections in immunocompromised patients who received investigational fecal microbiota transplantation; one patient died.[13] If someone proposes related research, check its research status, donor screening, and infection monitoring.

Can I withdraw after joining a trial?

Yes. In mainland China, for research covered by the ethical review measures mentioned above, participants or their guardians may withdraw unconditionally at any stage without first obtaining the investigator's approval.[16] Contact the investigator and your original transplant team as soon as possible to discuss safely stopping medicines, recommended follow-up, further treatment, medicine supply, and costs. Keep written contact details. In an emergency, seek medical care first.

How does news about TREGZI before transplant differ from treatment for GVHD now?

The FDA approval applies to specific adult patients with blood cancers undergoing transplant with a matched donor and myeloablative conditioning, with goals that include improving chronic GVHD-free survival. It is not evidence that an additional infusion can reverse established GVHD in any patient. US approval also does not mean it is available in mainland China.[14]

Sources

Date checked: November 6, 2026. Product and study status may change. Verify with the relevant institutions before proceeding.